Citations (87)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Nasimudeen R. Jabir, Khalid Anwar, Chelapram K. Firoz, Mohammad Oves, Mohammad Amjad Kamal & Shams Tabrez. (2018) An overview on the current status of cancer nanomedicines. Current Medical Research and Opinion 34:5, pages 911-921.
Read now
Read now
Gøril Eide Flaten, Ting-Tung Chang, William T. Phillips, Martin Brandl, Ande Bao & Beth Goins. (2013) Liposomal formulations of poorly soluble camptothecin: drug retention and biodistribution. Journal of Liposome Research 23:1, pages 70-81.
Read now
Read now
Hsin-I Chang & Ming-Kung Yeh. (2012) Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. International Journal of Nanomedicine 7, pages 49-60.
Read now
Read now
Gerard M. Jensen & Tarquinus H. Bunch. (2007) Conventional Liposome Performance and Evaluation: Lessons from the Development of Vescan. Journal of Liposome Research 17:3-4, pages 121-137.
Read now
Read now
Athanasios Fassas & Achilles Anagnostopoulos. (2005) The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leukemia & Lymphoma 46:6, pages 795-802.
Read now
Read now
L. Cattel, M. Ceruti & F. Dosio. (2004) From Conventional to Stealth Liposomes: a New Frontier in Cancer Chemotherapy. Journal of Chemotherapy 16:sup4, pages 94-97.
Read now
Read now
Atherton Gray, Darla J. Landfair & Marc E. Wiles. (1999) Cellular Uptake of Liposomal Daunorubicin and the Induction of Apoptosis. Drug Delivery 6:4, pages 213-226.
Read now
Read now
R. J. J. Lippens. (1999) LIPOSOMAL DAUNORUBICIN (DAUNOXOME) IN CHILDREN WITH RECURRENT OR PROGRESSIVE BRAIN TUMORS. Pediatric Hematology and Oncology 16:2, pages 131-139.
Read now
Read now
Marc E. Wiles, Carol Bell, Darla Landfair, Eric Lynam & R. A. Bendele. (1997) Anthracycline Efficacy in vitro: Cytotoxicity of Liposomal/Nonliposomal Daunorubicin and Doxorubicin for Multiple Tumor Cell Types. Drug Delivery 4:4, pages 255-262.
Read now
Read now
J. D. Lundgren. (1997) Kaposi's Sarcoma and its Management in AIDS Patients: Recommendations from a Scandinavian Study Group. Scandinavian Journal of Infectious Diseases 29:1, pages 3-12.
Read now
Read now
G. E. Francis, C. Delgado, D. Fisher, F. Malik & A. K. Agrawal. (1996) Polyethylene Glycol Modification: Relevance of Improved Methodology to Tumour Targeting. Journal of Drug Targeting 3:5, pages 321-340.
Read now
Read now
Mark Harrison, Kevin J Harrington & J Simon W Stewart. (1995) Section Review: Oncologic, Endocrine & Metabolic: Liposomal chemotherapy for AIDS-related Kaposi's sarcoma. Expert Opinion on Investigational Drugs 4:12, pages 1197-1203.
Read now
Read now
Alberto A. Gabizon. (1994) Liposomal Anthracyclines: Facing the Clinical Challenge. Journal of Liposome Research 4:1, pages 445-454.
Read now
Read now
Articles from other publishers (74)
Mariia Uzhytchak, Barbora Smolková, Mariia Lunova, Adam Frtús, Milan Jirsa, Alexandr Dejneka & Oleg Lunov. (2023) Lysosomal nanotoxicity: Impact of nanomedicines on lysosomal function. Advanced Drug Delivery Reviews 197, pages 114828.
Crossref
Crossref
Ashish Akkewar, Nilesh Mahajan, Rohini Kharwade & Purushottam Gangane. (2023) Liposomes in the Targeted Gene Therapy of Cancer: A Critical Review. Current Drug Delivery 20:4, pages 350-370.
Crossref
Crossref
Moreshwar P. Patil & Lalita S. Nemade. 2023. Advances in Novel Formulations for Drug Delivery. Advances in Novel Formulations for Drug Delivery
1
27
.
Mariana Neves Amaral, Jacinta O. Pinho, M. Manuela Gaspar & Catarina Pinto Reis. 2023. Phytopharmaceuticals and Herbal Drugs. Phytopharmaceuticals and Herbal Drugs
35
82
.
Tania B. Lopez-Mendez, Raffaele Strippoli, Flavia Trionfetti, Pilar Calvo, Marco Cordani & Juan Gonzalez-Valdivieso. 2023. Cancer Nanotechnology. Cancer Nanotechnology
325
383
.
Juanjuan Yang, Xiaojin Wang, Bingshun Wang, Kinam Park, Karen Wooley & Shiyi Zhang. (2022) Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers. Advanced Drug Delivery Reviews 190, pages 114525.
Crossref
Crossref
Ester Álvarez-Benedicto, Lukas Farbiak, Martha Márquez Ramírez, Xu Wang, Lindsay T. Johnson, Osamah Mian, Erick D. Guerrero & Daniel J. Siegwart. (2022) Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA). Biomaterials Science 10:2, pages 549-559.
Crossref
Crossref
Giovanna C. N. B. Lôbo, Karen L. R. Paiva, Ana Luísa G. Silva, Marina M. Simões, Marina A. Radicchi & Sônia N. Báo. (2021) Nanocarriers Used in Drug Delivery to Enhance Immune System in Cancer Therapy. Pharmaceutics 13:8, pages 1167.
Crossref
Crossref
Sandeep Kumar Singh, Umesh Kumar, Anupam Guleria & Dinesh Kumar. (2021) A brief overview about the use of different bioactive liposome-based drug delivery systems in Peritoneal Dialysis and some other diseases. Nano Express 2:2, pages 022006.
Crossref
Crossref
Peter Hoogevest, Harry Tiemessen, Josbert M. Metselaar, Simon Drescher & Alfred Fahr. (2021) The Use of Phospholipids to Make Pharmaceutical Form Line Extensions. European Journal of Lipid Science and Technology 123:4, pages 2000297.
Crossref
Crossref
Andrew Pradeep, R. Sethu Nagarajan & H. Fazil. 2021. Handbook of Research on Nano-Strategies for Combatting Antimicrobial Resistance and Cancer. Handbook of Research on Nano-Strategies for Combatting Antimicrobial Resistance and Cancer
294
305
.
Bruno Fonseca-Santos, Patrícia Bento da Silva, Josimar O. Eloy & Marlus Chorilli. 2021. Nanocarriers for Drug Delivery. Nanocarriers for Drug Delivery
223
252
.
Shashank Chaturvedi, Anuj Garg & Anurag Verma. (2020) Nano lipid based carriers for lymphatic voyage of anti-cancer drugs: An insight into the in-vitro, ex-vivo, in-situ and in-vivo study models. Journal of Drug Delivery Science and Technology 59, pages 101899.
Crossref
Crossref
Gerard M. Jensen & Donald F. Hodgson. (2020) Opportunities and challenges in commercial pharmaceutical liposome applications. Advanced Drug Delivery Reviews 154-155, pages 2-12.
Crossref
Crossref
Sonali S. Rohiwal & Arpita Pandey Tiwari. 2020. Nanomedicines for Breast Cancer Theranostics. Nanomedicines for Breast Cancer Theranostics
331
349
.
Ada Leung, Carolyn Amador, Lin Chuan Wang, Urmi Mody & Marcel Bally. (2019) What Drives Innovation: The Canadian Touch on Liposomal Therapeutics. Pharmaceutics 11:3, pages 124.
Crossref
Crossref
Sara Nidal Abed, Pran Kishore Deb, Hiba Salim Surchi, Sarah Falah Kokaz, Saadh Mohamed Jamal, Shantanu Bandopadhyay & Rakesh K. Tekade. 2019. Basic Fundamentals of Drug Delivery. Basic Fundamentals of Drug Delivery
685
731
.
Gopalakrishna Pillai. 2019. Applications of Targeted Nano Drugs and Delivery Systems. Applications of Targeted Nano Drugs and Delivery Systems
221
256
.
Ana Filipa Cruz, Nuno A. Fonseca, Ana C. Gregório, Vera Moura, Sérgio Simões & João Nuno Moreira. 2018. Particles and Nanoparticles in Pharmaceutical Products. Particles and Nanoparticles in Pharmaceutical Products
171
211
.
Upendra Bulbake, Sindhu Doppalapudi, Nagavendra Kommineni & Wahid Khan. (2017) Liposomal Formulations in Clinical Use: An Updated Review. Pharmaceutics 9:4, pages 12.
Crossref
Crossref
Alexandra G. Arranja, Vertika Pathak, Twan Lammers & Yang Shi. (2017) Tumor-targeted nanomedicines for cancer theranostics. Pharmacological Research 115, pages 87-95.
Crossref
Crossref
Phatsapong Yingchoncharoen, Danuta S. Kalinowski & Des R. Richardson. (2016) Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacological Reviews 68:3, pages 701-787.
Crossref
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
522
526
.
R.K. Kesrevani & A.K. Sharma. 2016. Nanoarchitectonics for Smart Delivery and Drug Targeting. Nanoarchitectonics for Smart Delivery and Drug Targeting
35
66
.
Dalit Landesman-Milo, Shahd Qassem & Dan Peer. 2016. Nanomedicine. Nanomedicine
131
155
.
James T. Cole & Nolan B. Holland. (2015) Multifunctional nanoparticles for use in theranostic applications. Drug Delivery and Translational Research 5:3, pages 295-309.
Crossref
Crossref
V Krishnan & A K Rajasekaran. (2013) Clinical Nanomedicine: A Solution to the Chemotherapy Conundrum in Pediatric Leukemia Therapy. Clinical Pharmacology & Therapeutics 95:2, pages 168-178.
Crossref
Crossref
Taraka Sai Pavan Grandhi & Kaushal Rege. 2014. Nanomaterial. Nanomaterial
157
182
.
Sylvie Crauste-Manciet, Eric Larquet, Karel Khawand, Michel Bessodes, Guy G. Chabot, Denis Brossard & Nathalie Mignet. (2013) Lipidic spherulites: Formulation optimisation by paired optical and cryoelectron microscopy. European Journal of Pharmaceutics and Biopharmaceutics 85:3, pages 1088-1094.
Crossref
Crossref
Ursula CreutzigMartin ZimmermannJean-Pierre BourquinMichael N. DworzakGudrun FleischhackNorbert GrafThomas KlingebielBernhard KremensThomas LehrnbecherChristine von NeuhoffJörg RitterAnnette SanderAndré SchrauderArend von Stackelberg, Jan Starý & Dirk Reinhardt. (2013) Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood 122:1, pages 37-43.
Crossref
Crossref
Gopalakrishna Pillai & Maria L Ceballos-Coronel. (2013) Science and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists. SAGE Open Medicine 1, pages 205031211351375.
Crossref
Crossref
Ruibing Wang, Paul S. Billone & Wayne M. Mullett. (2013) Nanomedicine in Action: An Overview of Cancer Nanomedicine on the Market and in Clinical Trials. Journal of Nanomaterials 2013, pages 1-12.
Crossref
Crossref
Wei Dong, Xiaojun Chen, Ke Liu, Haitao Chen & Zhiliang Sun. (2011) Serum antibody coupled with the construction of gentamicin sulfate for the Escherichia coli targeted drug. Research in Veterinary Science 91:3, pages e136-e143.
Crossref
Crossref
Kevin J Harrington, Konstantinos N Syrigos & Richard G Vile. (2002) Liposomally targeted cytotoxic drugs for the treatment of cancer. Journal of Pharmacy and Pharmacology 54:12, pages 1573-1600.
Crossref
Crossref
. 2010. Meyler's Side Effects of Drugs in Cancer and Immunology. Meyler's Side Effects of Drugs in Cancer and Immunology
1
229
.
Ray Wood, James McShane, Robert Lee, J Michael Shaw & Dinesh Shenoy. 2008. Water-Insoluble Drug Formulation, Second Edition. Water-Insoluble Drug Formulation, Second Edition
467
498
.
Stephen Lowis. (2008) Drug Delivery Systems in Children. Pediatric Drugs 10:6, pages 351-355.
Crossref
Crossref
Ursula Creutzig, Sylke Diekamp, Martin Zimmermann & Dirk Reinhardt. (2007) Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML. Pediatric Blood & Cancer 48:7, pages 651-662.
Crossref
Crossref
S Lowis, I Lewis, A Elsworth, C Weston, F Doz, G Vassal, R Bellott, J Robert, F Pein, S Ablett, R Pinkerton & D Frappaz. (2006) A phase I study of intravenous liposomal daunorubicin (DaunoXome) in paediatric patients with relapsed or resistant solid tumours. British Journal of Cancer 95:5, pages 571-580.
Crossref
Crossref
. 2006. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions
255
260
.
Frederico Luiz Dulley, Rosaura Saboya, Vânia Tietsche de Moraes Hungria, Nadjanara Dorna Bueno, Fernando Gomes de Mello, Maria Tereza Frota, Carlos Sergio Chiattone, José Carlos Barros, Nair Sumie Mori, Daniel Sturaro, Maria Cristina Martins de Almeida Macedo, Roberto Luiz da Silva, Leila Maria Magalhães Pessoa de Melo & Cármino Antonio Souza. (2005) Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol. Sao Paulo Medical Journal 123:6, pages 266-270.
Crossref
Crossref
Xin-Ming Liu, Bin Yang, Yu-Lu Wang & Jin-Ye Wang. (2005) New Nanoscale Pulsatile Drug Delivery System. Chemistry of Materials 17:11, pages 2792-2795.
Crossref
Crossref
Klaus Mross, Ulrich Massing & Felix Kratz. 2005. Drugs Affecting Growth of Tumours. Drugs Affecting Growth of Tumours
19
81
.
Giorgio Minotti, Pierantonio Menna, Emanuela Salvatorelli, Gaetano Cairo & Luca Gianni. (2004) Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacological Reviews 56:2, pages 185-229.
Crossref
Crossref
Sushma Kommareddy & Mansoor Amiji. 2004. Cellular Drug Delivery. Cellular Drug Delivery
181
215
.
Georg Hempel, Dirk Reinhardt, Ursula Creutzig & Joachim Boos. (2003) Population pharmacokinetics of liposomal daunorubicin in children. British Journal of Clinical Pharmacology 56:4, pages 370-377.
Crossref
Crossref
Luigi Cattel, Maurizio Ceruti & Franco Dosio. (2018) From Conventional to Stealth Liposomes a new Frontier in Cancer Chemotherapy. Tumori Journal 89:3, pages 237-249.
Crossref
Crossref
Federico Pea, Domenico Russo, Mariagrazia Michieli, Daniela Damiani, Renato Fanin, Angela Michelutti, Teresa Michelutti, Stefano Piccolrovazzi, Michele Baccarani & Mario Furlanut. (2003) Disposition of Liposomal Daunorubicin During Cotreatment with Cytarabine in Patients with Leukaemia. Clinical Pharmacokinetics 42:9, pages 851-862.
Crossref
Crossref
Nina Griese, Gottfried Blaschke, Joachim Boos & Georg Hempel. (2002) Determination of free and liposome-associated daunorubicin and daunorubicinol in plasma by capillary electrophoresis. Journal of Chromatography A 979:1-2, pages 379-388.
Crossref
Crossref
K J O'Byrne, A L Thomas, R A Sharma, M DeCatris, F Shields, S Beare & W P Steward. (2002) A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. British Journal of Cancer 87:1, pages 15-20.
Crossref
Crossref
A. Fassas, R. Buffels, A. Anagnostopoulos, E. Gacos, C. Vadikolia, P. Haloudis & P. Kaloyannidis. (2002) Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study. British Journal of Haematology 116:2, pages 308-315.
Crossref
Crossref
Judith Fraser, Chris Twelves & Andrew Stanley. 2002.
533
552
.
Georg Hempel, Petra Schulze-Westhoff, Silke Flege & Joachim Boos. (2001) Quantification of daunorubicin and daunorubicinol in plasma by capillary electrophoresis. Journal of Chromatography B: Biomedical Sciences and Applications 758:2, pages 221-228.
Crossref
Crossref
C. Lerchenmüller, W. E. Berdel & T. BÜchner. 2001. Acute Leukemias VIII. Acute Leukemias VIII
191
195
.
I.W. Flinn, S.N. Goodman, L. Post, J. Jamison, C.B. Miller, S. Gore, L. Diehl, C. Willis, R.F. Ambinder & J.C. Byrd. (2000) A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL. Annals of Oncology 11:6, pages 691-695.
Crossref
Crossref
K.J. Harrington, C.R. Lewanski & J.S.W. Stewart. (2000) Liposomes as Vehicles for Targeted Therapy of Cancer. Part 1: Preclinical Development. Clinical Oncology 12:1, pages 2-15.
Crossref
Crossref
A Nagayasu, K Uchiyama & H Kiwada. (1999) The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Advanced Drug Delivery Reviews 40:1-2, pages 75-87.
Crossref
Crossref
Mariagrazia Michieli, Daniela Damiani, Anna Ermacora, Paola Masolini, Angela Michelutti, Teresa Michelutti, Domenico Russo, Federico Pea & Michele Baccarani. (2008) Liposome‐encapsulated daunorubicin for PGP‐related multidrug resistance. British Journal of Haematology 106:1, pages 92-99.
Crossref
Crossref
Jetske M.Meerum Terwogt, Jan H.M. Schellens, Wim W.ten Bokkel Huinink & Jos H. Beijnen. (1999) Clinical pharmacology of anticancer agents in relation to formulations and administration routes. Cancer Treatment Reviews 25:2, pages 83-102.
Crossref
Crossref
S.D. Fosså, N. Aass & G. Parö. (1998) A phase II study of DaunoXome® in advanced urothelial transitional cell carcinoma. European Journal of Cancer 34:7, pages 1131-1132.
Crossref
Crossref
Martin C Woodle. (1998) Controlling liposome blood clearance by surface-grafted polymers. Advanced Drug Delivery Reviews 32:1-2, pages 139-152.
Crossref
Crossref
G. Pratt, M. E. Wiles, A. C. Rawstron, F. E. Davies, J. A. L. Fenton, J. A. Proffitt, J. A. Child, G. M. Smith & G. J. Morgan. (1998) Liposomal daunorubicin:in vitro andin vivo efficacy in multiple myeloma. Hematological Oncology 16:2, pages 47-55.
Crossref
Crossref
S.A. Johnson & D.S. Richardson. (1998) Anthracyclines in haematology: pharmacokinetics and clinical studies. Blood Reviews 12:1, pages 52-71.
Crossref
Crossref
PAUL G. SCHMIDT, JILL P. ADLER-MOORE, ERIC A. FORSSEN & RICHARD T. PROFFITT. 1998. Medical Applications of Liposomes. Medical Applications of Liposomes
703
731
.
ALBERTO A. GABIZON. 1998. Medical Applications of Liposomes. Medical Applications of Liposomes
625
634
.
Eric A. Forssen & Richard T. Proffitt. 1998. Long Circulating Liposomes: Old Drugs, New Therapeutics. Long Circulating Liposomes: Old Drugs, New Therapeutics
73
96
.
Geoffrey Mukwaya, Eric A. Forssen, Paul Schmidt & Michael Ross. 1998. Long Circulating Liposomes: Old Drugs, New Therapeutics. Long Circulating Liposomes: Old Drugs, New Therapeutics
147
163
.
Gerrit Storm & Martin C. Woodle. 1998. Long Circulating Liposomes: Old Drugs, New Therapeutics. Long Circulating Liposomes: Old Drugs, New Therapeutics
3
16
.
Deborah S. Richardson, Stephen M. Kelsey, Stephen A. Johnson, Mary Tighe, James D. Cavenagh & Adrian C. Newland. (1997) Early evaluation of liposomal daunorubicin (DaunoXome®, Nexstar) in the treatment of relapsed and refractory lymphoma. Investigational New Drugs 15:3, pages 247-253.
Crossref
Crossref
Eric A. Forssen. (1997) The design and development of DaunoXome® for solid tumor targeting in vivo. Advanced Drug Delivery Reviews 24:2-3, pages 133-150.
Crossref
Crossref
M. Ranson, A. Howell, S. Cheeseman & J. Margison. (1996) Liposomal drug delivery. Cancer Treatment Reviews 22:5, pages 365-379.
Crossref
Crossref
Robert Janknegt. (1996) Liposomal formulations of cytotoxic drugs. Supportive Care in Cancer 4:4, pages 298-304.
Crossref
Crossref
Paul Pouna, Simone Bonoron-Adèle, Gérard Gouverneur, Liliane Tariosse, Pierre Besse & Jacques Robert. (1996) Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. British Journal of Pharmacology 117:7, pages 1593-1599.
Crossref
Crossref
Gregory Gregoriadis. (1995) Engineering liposomes for drug delivery: progress and problems. Trends in Biotechnology 13:12, pages 527-537.
Crossref
Crossref